Stephan, C., Jung, K., Lein, M., Schnorr, D. and Loening, S.A. (2000) Re: Complexed Prostate Specific Antigen Provides Significant Enhancement of Specificity Compared with Total Prostate Specific Antigen for Detecting Prostate Cancer. Journal of Urology, 164, 1671-1672.
https://doi.org/10.1016/S0022-5347(05)67079-6

has been cited by the following article:

• TITLE: Promoter Region Analysis of STAMP1/STEAP2 Gene-Silencing of STAMP1/STEAP2 Gene Triggers P53 Upregulation

  AUTHORS: Ceren Gönen

  KEYWORDS: LNCaP, STAMP1/STEAP2, P53, RT-PCR

  JOURNAL NAME: CellBio, Vol.12 No.1, March 27, 2023

  ABSTRACT: Prostate cancer is the most commonly diagnosed cancer and the second leading cause of cancer mortality in men in the Western World. In the initial stages, prostate cancer is dependent on androgens for growth which is the basis for androgen ablation therapy. The effects of androgens are mediated by the Androgen Receptor (AR). Therefore, studies focus on the identification of AR-regulated genes that are also highly expressed in the prostate. STAMP family genes STAMP1/STEAP2 and STAMP2/STEAP4 have only expressed in androgen receptor-positive cells, the role of AR in STAMP family gene expression is an important question. STEAP (Six Transmembrane Epithelial Antigen of Prostate) is the first characterized prostate of enriched six transmembrane gene, expressed in metastatic prostate cancer samples, it is tempting to speculate that STAMP/STEAP family genes may be involved in similar functions with a role for both the normal biology and pathophysiology of the prostate. Using siRNA technology in LNCaP cells expressing STAMP genes per se, an apoptosis panel including pro-apoptotic and/or apoptotic molecules was assayed by RT-PCR, By this research project, prostate-specific STAMP gene family and its regulatory effects on the p53- and caspase-related pathways were characterized.